rLP2086 + MCV4 + Tdap + MCV4 + Tdap + saline + rLP2086 + saline
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vaccines
Conditions
Vaccines, Meningococcal Vaccines
Trial Timeline
Sep 28, 2011 → May 8, 2014
NCT ID
NCT01461980About rLP2086 + MCV4 + Tdap + MCV4 + Tdap + saline + rLP2086 + saline
rLP2086 + MCV4 + Tdap + MCV4 + Tdap + saline + rLP2086 + saline is a phase 2 stage product being developed by Pfizer for Vaccines. The current trial status is completed. This product is registered under clinical trial identifier NCT01461980. Target conditions include Vaccines, Meningococcal Vaccines.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01461980 | Phase 2 | Completed |
Competing Products
20 competing products in Vaccines